Trevi Therapeutics, Inc
Price
FilingsNewest: 10-Q, Quarterly reportAug 6 →InsidersNo open-market buys or sales.→HoldersNea 9.3%FMR 8.8%BlackRock 7.8%→Financing →PeersClosest companies: AXSM, VRDN, SPRO→
From the filings
Figures
- Net income
- −$51.1Mlast 12 months
- Operating cash flow
- −$45.3Mlast 12 months
- Cash and equivalents
- $54.3Mat the last balance sheet
- Shares outstanding
- 142.4M shareson issue